Streetbeat News

Stock Prices

BLND

Blend Labs, Inc. (BLND) will join the Russell 2000 Index on July 1, 2024, as part of the annual reconstitution.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:15 pm

MYGN

Myriad Genetics' Patient-Outcomes Study validating RiskScore as a clinical breast cancer risk assessment tool has been published in Medical Genetics and Genomics.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:13 pm

GTLB

GitLab has raised its fiscal year 2025 revenue outlook from $725M-$731M to $733M-$737M, and adjusted EPS from $0.19-$0.23 to $0.34-$0.37. This update comes after completing the fiscal year 2025 SSP allocation analysis, which resulted in a $4 million headwind to revenue guidance. Despite this, the company has increased its guidance due to first-quarter top-line outperformance.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:12 pm

FGEN

REGN

FibroGen shares are trading higher after the company announced that the FDA cleared its Investigational New Drug FG-3165. Additionally, FibroGen has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FG-3165 and FG-3175 in combination with LIBTAYO.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:10 pm

LL

F9 Investments is urging shareholders to vote for its director nominees on the GOLD proxy card, criticizing LL Flooring's strategic plan and leadership for a 93% stock price decline. F9 highlights the auditor's going concern disclosure and endorses nominees Tom Sullivan, Jason Delves, and Jill Witter to restore value.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:08 pm

GTLB

GitLab has announced its Q2 revenue expectations to be between $176M and $177M, slightly above the estimated $176.733M. The company also expects an adjusted EPS of $0.09 to $0.10, significantly higher than the estimated $0.05.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:08 pm

VCYT

Veracyte has reported new research utilizing its Afirma Genomic Resource for Intelligent Discovery (GRID) tool. This development could have implications for the company's future growth and market position.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:07 pm

GTLB

GitLab (NASDAQ:GTLB) reported Q1 2025 earnings of $0.03 per share, significantly beating the analyst estimate of $(0.04). Sales also surpassed expectations, reaching $169.187 million, a 33.35% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:06 pm

BARK

BARK shares are trading lower after the company reported worse-than-expected Q4 financial results and issued Q1 and FY25 revenue guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:06 pm

ASND

Ascendis Pharma A/S (NASDAQ:ASND) presented new data and updated results from its Phase 1/2 IL-Believe Trial at ASCO 2024. The trial showed promising clinical responses in patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ, both as monotherapy and in combination with TransCon TLR7/8 Agonist.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:05 pm